Research location
Layton
Utah, United States
Advertisement
Research activity in Layton
Utah, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 54 trials and 54 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Layton
54 linked trials · page 1 of 2AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes MedicationsNCT07797335 · 2026-08-24 · 1 site observation
RECRUITING
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)NCT07684235 · 2026-07-23 · 1 site observation
RECRUITING
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285 · 2026-01-08 · 1 site observation
RECRUITING
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseNCT07181109 · 2025-09-22 · 1 site observation
RECRUITING
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)NCT06857942 · 2025-03-19 · 1 site observation
RECRUITING
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor AntagonistsNCT06033950 · 2024-08-20 · 1 site observation
RECRUITING
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)NCT06024746 · 2024-07-09 · 1 site observation
RECRUITING
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)NCT06439277 · 2024-06-03 · 1 site observation
RECRUITING
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or ObesityNCT07861100 · 2026-10-26 · 1 site observation
NOT_YET_RECRUITING
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858878 · 2025-03-17 · 1 site observation
ACTIVE_NOT_RECRUITING
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858839 · 2025-03-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic DiseaseNCT06760637 · 2025-01-06 · 1 site observation
ACTIVE_NOT_RECRUITING
Nipocalimab in Moderate to Severe Sjogren's DiseaseNCT06741969 · 2024-12-04 · 1 site observation
ACTIVE_NOT_RECRUITING
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or OverweightNCT06588283 · 2024-09-30 · 1 site observation
COMPLETED
A Study to Evaluate Solrikitug in Participants With COPD (ZION)NCT06496620 · 2024-08-14 · 1 site observation
ACTIVE_NOT_RECRUITING
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 · 2024-04-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Vasopressin for Septic Shock Pragmatic TrialNCT06217562 · 2024-02-01 · 1 site observation
COMPLETED
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 · 2023-11-20 · 1 site observation
COMPLETED
Study of Evobrutinib in Participants With RMS (evolutionRMS 1)NCT04338022 · 2020-06-12 · 1 site observation
TERMINATED
Registry of Asthma Patients Initiating DUPIXENT®NCT04287621 · 2020-03-02 · 1 site observation
COMPLETED
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With SulfonylureaNCT03770728 · 2019-08-01 · 1 site observation
TERMINATED
Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness StudyNCT03949842 · 2019-06-27 · 1 site observation
WITHDRAWN
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)NCT03713684 · 2018-11-09 · 1 site observation
TERMINATED
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With MetforminNCT03684642 · 2018-09-26 · 1 site observation
TERMINATED
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04NCT03383146 · 2018-02-01 · 1 site observation
TERMINATED
Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver DiseaseNCT03371355 · 2017-12-21 · 1 site observation
COMPLETED
An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential HypertensionNCT03514641 · 2017-10-18 · 1 site observation
COMPLETED
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01NCT03285308 · 2017-09-29 · 1 site observation
TERMINATED
A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar ControlNCT03242018 · 2017-08-16 · 1 site observation
COMPLETED
Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar ControlNCT03242252 · 2017-08-16 · 1 site observation
COMPLETED
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 DiabetesNCT03235050 · 2017-08-02 · 1 site observation
COMPLETED
Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's SyndromeNCT03100942 · 2017-05-01 · 1 site observation
COMPLETED
Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes MellitusNCT02465515 · 2015-07-01 · 1 site observation
COMPLETED
Cardiovascular Inflammation Reduction TrialNCT01594333 · 2013-04-01 · 1 site observation
COMPLETED
Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese PatientsNCT01602367 · 2012-07-01 · 1 site observation
TERMINATED
Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular DiseaseNCT01609582 · 2012-06-01 · 1 site observation
TERMINATED
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma MedicationsNCT01576718 · 2012-04-01 · 1 site observation
COMPLETED
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing SteroidsNCT01479621 · 2012-01-01 · 1 site observation
COMPLETED
A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and AdolescentsNCT01444430 · 2011-12-01 · 1 site observation
COMPLETED
SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.NCT01475721 · 2011-11-18 · 1 site observation
COMPLETED
6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years OldNCT01462344 · 2011-11-17 · 1 site observation
COMPLETED
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes MellitusNCT01144338 · 2010-06-18 · 1 site observation
COMPLETED
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes MellitusNCT01042769 · 2010-02-01 · 1 site observation
COMPLETED
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab AloneNCT00968968 · 2010-01-20 · 1 site observation
TERMINATED
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart FailureNCT01035255 · 2009-12-01 · 1 site observation
TERMINATED
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's DiseaseNCT01320527 · 2008-08-01 · 1 site observation
COMPLETED
Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma HistologyNCT00596830 · 2008-04-01 · 1 site observation
TERMINATED
A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib AloneNCT00457392 · 2007-07-01 · 1 site observation
COMPLETED
A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast CancerNCT00435409 · 2007-02-01 · 1 site observation
COMPLETED
Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular SafetyNCT00359801 · 2006-07-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.